Bibliografías temáticas / Antithrombotic strategies

Índice

  1. Artículos de revistas
  2. Tesis
  3. Libros
  4. Capítulos de libros

Literatura académica sobre el tema "Antithrombotic strategies"

Autor: Grafiati
Publicado: 10 de marzo de 2023

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Antithrombotic strategies".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Artículos de revistas sobre el tema "Antithrombotic strategies"

1

Guedeney, Paul y Jean-Philippe Collet. "Antithrombotic strategies following TAVR". Sang thrombose vaisseaux 33, n.º 1 (febrero de 2021): 19–24. http://dx.doi.org/10.1684/stv.2021.1155.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Hasan, Md Nazmul, Md Abu Siddique, Sajal Krishna Banerjee, Syed Ali Ahsan, AKM Fazlur Rahman, Choudhury Meshkat Ahmed, Mohammad Faisal Ibn Kabir y Md Harisul Hoque. "Antithrombotic Strategies in Perioperative Period". University Heart Journal 9, n.º 1 (14 de julio de 2014): 47–51. http://dx.doi.org/10.3329/uhj.v9i1.19511.

Texto completo
Resumen
Antithrombotic therapy (Warfarin, Aspirin,Clopidogrel etc.) are routinely used in prevention and treatment of various cardiovascular diseases. In patients who are having a surgical or other invasive procedure, interruption of antithrombotic therapy is typically required to minimize the risk for perioperative bleeding. It involves balancing the risk of periprocedural bleeding with continued treatment against the thrombotic risk with suspension of treatment and use of bridging anticoagulation therapy. The need for bridging is driven by patients’ estimated risk for thromboembolism and the bleeding risk of invasive procedure. Treatment with subcutaneous low-molecular- weight heparin or intravenous unfractionated heparin at a therapeutic dose before and after the procedure recommended as bridging anticoagulation therapy. DOI: http://dx.doi.org/10.3329/uhj.v9i1.19511 University Heart Journal Vol. 9, No. 1, January 2013; 47-51
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Gremmel, Thomas y Kurt Huber. "Antithrombotic treatment strategies after PCI". Lancet 395, n.º 10227 (marzo de 2020): 865. http://dx.doi.org/10.1016/s0140-6736(20)30028-3.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

De Caterina, Raffaele y Ugo Limbruno. "Antithrombotic treatment strategies after PCI". Lancet 395, n.º 10227 (marzo de 2020): 865. http://dx.doi.org/10.1016/s0140-6736(20)30029-5.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Jeong, Young-Hoon, Yong-Lee Kim, Udaya Tantry y Paul A. Gurbel. "Antithrombotic treatment strategies after PCI". Lancet 395, n.º 10227 (marzo de 2020): 866–67. http://dx.doi.org/10.1016/s0140-6736(20)30030-1.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Romiti, Giulio Francesco, Stefania Basili y Marco Proietti. "Antithrombotic treatment strategies after PCI". Lancet 395, n.º 10227 (marzo de 2020): 866. http://dx.doi.org/10.1016/s0140-6736(20)30031-3.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Auer, Johann, Robert Berent y Franz Gurtner. "Antithrombotic treatment strategies after PCI". Lancet 395, n.º 10227 (marzo de 2020): 865–66. http://dx.doi.org/10.1016/s0140-6736(20)30032-5.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Channon, Keith M. y Brian H. Annex. "Antithrombotic strategies in gene therapy". Current Cardiology Reports 2, n.º 1 (enero de 2000): 34–38. http://dx.doi.org/10.1007/s11886-000-0023-4.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Gurbel, Paul A., Palak Shah, Shashank Desai y Udaya S. Tantry. "Antithrombotic Strategies and Device Thrombosis". Cardiology Clinics 36, n.º 4 (noviembre de 2018): 541–50. http://dx.doi.org/10.1016/j.ccl.2018.06.008.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Shishehbor, Mehdi H. y Barry T. Katzen. "Antithrombotic Strategies in Endovascular Interventions". Interventional Cardiology Clinics 2, n.º 4 (octubre de 2013): 627–33. http://dx.doi.org/10.1016/j.iccl.2013.06.005.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
Más fuentes

Tesis sobre el tema "Antithrombotic strategies"

1

Bellandi, Benedetta. "Pharmacodynamic of antithrombotic therapies in high cardiovascular risk patients". Doctoral thesis, 2018. http://hdl.handle.net/2158/1129305.

Texto completo
Resumen
This thesis addresses different aspects of antithrombotic strategies in patients with acute coronary syndrome, mainly in ST elevation acute myocardial infarction (STEMI) patients treated with percutaneous coronary intervention (PCI), regarding their efficacy and safety during the acute phase as well as their appropriateness and impact on long-term outcomes.
Los estilos APA, Harvard, Vancouver, ISO, etc.

Libros sobre el tema "Antithrombotic strategies"

1

Askari, Arman. Management strategies in antithrombotic therapy. Chichester: John Wiley and Sons, 2007.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Askari, Arman, Michael Lincoff y Adrian Messerli. Management Strategies in Antithrombotic Therapy. Wiley & Sons, Incorporated, John, 2008.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Askari, Arman, Michael Lincoff y Adrian Messerli. Management Strategies in Antithrombotic Therapy. Wiley & Sons, Limited, John, 2007.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Management Strategies in Antithrombotic Therapy. Wiley-Interscience, 2008.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

McDonald, Vickie y Marie Scully. Anticoagulants and antithrombotics in critical illness. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0051.

Texto completo
Resumen
Coagulation is best thought of using the cell-based model of coagulation. Patients commenced on heparin therapy should have their platelet count monitored early because of the risk of heparin-induced thrombocytopenia, which can occur on any type or dose of heparin. Emergency reversal of warfarin should be with prothrombin complex concentrate (containing factors II, VII, IX, and X) and not fresh frozen plasma. New oral anticoagulants have the advantage of predictable pharmacokinetics and do not require routine monitoring, but optimal reversal strategies for these agents are not clear. Thrombolytic agents lead to variable degrees of systemic lysis, which may cause haemorrhage, including intracerebral haemorrhage
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Mannucci, Pier Mannuccio. Bleeding and haemostasis disorders. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199687039.003.0070.

Texto completo
Resumen
The main cause of haemostasis defects and related bleeding complications in patients with acute coronary syndromes admitted to the intensive cardiac care unit is the use of multiple antithrombotic drugs, alone or concomitantly with invasive procedures such as percutaneous coronary intervention with stent deployment and coronary artery bypass surgery. These drugs, that act upon several components of haemostasis (platelet function, coagulation, fibrinolysis), are associated with bleeding complications, particularly in elderly patients (more so in women than in men), those who are underweight, and those with comorbid conditions such as renal and liver insufficiency and diabetes. The identification of patients at higher risk of bleeding is the most important preventive strategy. Red cell and platelet transfusions, which may become necessary in patients with severe bleeding, should be used with caution, because transfused patients with acute coronary syndrome have a high rate of adverse outcomes (death, myocardial infarction, and stroke). To reduce the need of transfusion, haemostatic agents that decrease blood loss and transfusion requirements (antifibrinolytic amino acids, plasmatic prothrombin complex concentrates, recombinant factor VIIa) may be considered. However, the efficacy of these agents in the control of bleeding complications in acute coronary syndrome is not unequivocally established, and there is concern for an increased risk of re-thrombosis. A low platelet count is another cause of bleeding in the intensive cardiac care unit. The main aetiologies are drugs (unfractionated heparin and glycoprotein IIb/IIIa inhibitors), thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura, and disseminated intravascular coagulation, that are often paradoxically associated with thrombotic manifestations. In conclusion, evidence-based recommendations for the management of bleeding in patients admitted to the intensive cardiac care unit are lacking. Accurate assessments of the risk of bleeding in the individual and prevention measures are the most valid strategies.
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Mannucci, Pier Mannuccio. Bleeding and haemostasis disorders. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199687039.003.0070_update_001.

Texto completo
Resumen
The main cause of haemostasis defects and related bleeding complications in patients with acute coronary syndromes admitted to the intensive cardiac care unit is the use of multiple antithrombotic drugs, alone or concomitantly with invasive procedures such as percutaneous coronary intervention with stent deployment and coronary artery bypass surgery. These drugs, that act upon several components of haemostasis (platelet function, coagulation, fibrinolysis), are associated with bleeding complications, particularly in elderly patients (more so in women than in men), those who are underweight, and those with comorbid conditions such as renal and liver insufficiency and diabetes. The identification of patients at higher risk of bleeding is the most important preventive strategy. Red cell and platelet transfusions, which may become necessary in patients with severe bleeding, should be used with caution, because transfused patients with acute coronary syndrome have a high rate of adverse outcomes (death, myocardial infarction, and stroke). To reduce the need of transfusion, haemostatic agents that decrease blood loss and transfusion requirements (antifibrinolytic amino acids, plasmatic prothrombin complex concentrates, recombinant factor VIIa) may be considered. However, the efficacy of these agents in the control of bleeding complications in acute coronary syndrome is not unequivocally established, and there is concern for an increased risk of re-thrombosis. A low platelet count is another cause of bleeding in the intensive cardiac care unit. The main aetiologies are drugs (unfractionated heparin and glycoprotein IIb/IIIa inhibitors), thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura, and disseminated intravascular coagulation, that are often paradoxically associated with thrombotic manifestations. In conclusion, evidence-based recommendations for the management of bleeding in patients admitted to the intensive cardiac care unit are lacking. Accurate assessments of the risk of bleeding in the individual and prevention measures are the most valid strategies.
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Mannucci, Pier Mannuccio. Bleeding and haemostasis disorders. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199687039.003.0070_update_002.

Texto completo
Resumen
The main cause of haemostasis defects and related bleeding complications in patients with acute coronary syndromes admitted to the intensive cardiac care unit is the use of multiple antithrombotic drugs, alone or concomitantly with invasive procedures such as percutaneous coronary intervention with stent deployment and coronary artery bypass surgery. These drugs, that act upon several components of haemostasis (platelet function, coagulation, fibrinolysis), are associated with bleeding complications, particularly in elderly patients (more so in women than in men), those who are underweight, and those with comorbid conditions such as renal and liver insufficiency and diabetes. The identification of patients at higher risk of bleeding is the most important preventive strategy. Red cell and platelet transfusions, which may become necessary in patients with severe bleeding, should be used with caution, because transfused patients with acute coronary syndrome have a high rate of adverse outcomes (death, myocardial infarction, and stroke). To reduce the need of transfusion, haemostatic agents that decrease blood loss and transfusion requirements (antifibrinolytic amino acids, plasmatic prothrombin complex concentrates, recombinant factor VIIa) may be considered. However, the efficacy of these agents in the control of bleeding complications in acute coronary syndrome is not unequivocally established, and there is concern for an increased risk of re-thrombosis. A low platelet count is another cause of bleeding in the intensive cardiac care unit. The main aetiologies are drug usage (unfractionated heparin and glycoprotein IIb/IIIa inhibitors), such thrombotic microangiopathies as thrombotic thrombocytopenic purpura and disseminated intravascular coagulation, that are often paradoxically associated with thrombotic manifestations. In conclusion, evidence-based recommendations for the management of bleeding in patients admitted to the intensive cardiac care unit are lacking. Accurate assessments of the risk of bleeding in the individual and prevention measures are the most valid strategies.
Los estilos APA, Harvard, Vancouver, ISO, etc.

Capítulos de libros sobre el tema "Antithrombotic strategies"

1

Bitar, Jamil, Salim Dabaghi, Selim Sekili y Neil S. Kleiman. "Novel Antithrombotic Strategies". En Unstable Coronary Artery Syndromes Pathophysiology, Diagnosis and Treatment, 241–75. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-5715-9_7.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Leblond, L. y P. D. Winocour. "The Coagulation Pathway and Antithrombotic Strategies". En Antithrombotics, 1–39. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59942-2_1.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Shishehbor, Mehdi H. "Antithrombotic Strategies in Endovascular Interventions". En Interventional Cardiology, 754–58. Chichester, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118983652.ch82.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Schoos, Mikkel Malby, Davide Capodanno y George D. Dangas. "Antithrombotic Strategies in Valvular and Structural Heart Disease Interventions". En Interventional Cardiology, 507–16. Chichester, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118983652.ch53.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Rao, Sunil V. y E. Magnus Ohman. "Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention". En Therapeutic Advances in Thrombosis, 236–45. Oxford, UK: Blackwell Publishing Ltd., 2012. http://dx.doi.org/10.1002/9781118410875.ch16.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Deckmyn, H., P. Gresele, J. Arnout y J. Vermylen. "Manipulation of Pro- and Antiaggregating Prostaglandins: New Antithrombotic Strategies". En Drugs Affecting Leukotrienes and Other Eicosanoid Pathways, 141–47. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4684-7841-9_12.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Margaglione, M., E. Grandone, F. P. Mancini y G. Di Minno. "Drugs affecting plasma fibrinogen levels. Implications for new antithrombotic strategies". En Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques, 169–81. Basel: Birkhäuser Basel, 1996. http://dx.doi.org/10.1007/978-3-0348-8996-4_4.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Wali, Eisha y Sandeep Nathan. "Newest Antithrombotic Agents: Uses, Challenges, and Reversal Strategies for Surgical Procedures". En Difficult Decisions in Surgery: An Evidence-Based Approach, 481–97. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-04146-5_33.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Mejevoi, Nicolai, Catalin Boiangiu y Marc Cohen. "Antiplatelet therapy versus other antithrombotic strategies". En Platelets in Hematologic and Cardiovascular Disorders, 367–85. Cambridge University Press, 2001. http://dx.doi.org/10.1017/cbo9780511545276.023.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Kristensen, Steen D., Kurt Huber y Michael Maeng. "Risk reduction strategies: perioperative management in patients on antithrombotic therapy". En ESC CardioMed, editado por Steen Kristensen, 2657–59. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0638.

Texto completo
Resumen
The choice of disruption or continuation of antithrombotic drugs prior to non-cardiac surgery is a challenging issue for surgeons and cardiologists. The type of surgery, cardiac diagnosis, and indication for antithrombotic therapy should be evaluated and discussed. This chapter provides some guidance for clinicians on how to balance bleeding and perioperative thrombotic complications.
Los estilos APA, Harvard, Vancouver, ISO, etc.
También puede estar interesado en las bibliografías ampliadas sobre el tema "Antithrombotic strategies" para tipos de fuentes particulares:
Artículos de revistas
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía